Europeiska unionen - svenska - EMA (European Medicines Agency)

serb sa - betaine - homocystinuri - andra matsmältningsorgan och ämnesomsättning produkter, - amversio is indicated as adjunctive treatment of homocystinuria, involving deficiencies or defects in:•         cystathionine beta-synthase (cbs),•         5,10 methylene tetrahydrofolate reductase (mthfr),•         cobalamin cofactor metabolism (cbl).

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Europeiska unionen - svenska - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doxorubicinhydroklorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiska medel - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz a/s - isoniazid; rifampicin - filmdragerad tablett - 150 mg/75 mg - rifampicin 150 mg aktiv substans; isoniazid 75 mg aktiv substans; natriumlaurilsulfat hjälpämne - rifampicin och isoniazid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - isoniazid; rifampicin - filmdragerad tablett - 150 mg/75 mg - natriumlaurilsulfat hjälpämne; rifampicin 150 mg aktiv substans; isoniazid 75 mg aktiv substans - rifampicin och isoniazid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz a/s - etambutolhydroklorid; isoniazid; pyrazinamid; rifampicin - filmdragerad tablett - 150 mg/75 mg/400 mg/275 mg - rifampicin 150 mg aktiv substans; natriumlaurilsulfat hjälpämne; isoniazid 75 mg aktiv substans; etambutolhydroklorid 275 mg aktiv substans; pyrazinamid 400 mg aktiv substans - etambutol och isoniazid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - etambutolhydroklorid; isoniazid; pyrazinamid; rifampicin - filmdragerad tablett - 150 mg/75 mg/400 mg/275 mg - pyrazinamid 400 mg aktiv substans; etambutolhydroklorid 275 mg aktiv substans; natriumlaurilsulfat hjälpämne; isoniazid 75 mg aktiv substans; rifampicin 150 mg aktiv substans - etambutol och isoniazid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz a/s - isoniazid; pyrazinamid; rifampicin - filmdragerad tablett - 150 mg/75 mg/400 mg - isoniazid 75 mg aktiv substans; natriumlaurilsulfat hjälpämne; rifampicin 150 mg aktiv substans; pyrazinamid 400 mg aktiv substans - pyrazinamid och isoniazid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - etambutolhydroklorid; isoniazid; pyrazinamid; rifampicin - filmdragerad tablett - 150 mg/75 mg/400 mg/275 mg - isoniazid 75 mg aktiv substans; etambutolhydroklorid 275 mg aktiv substans; rifampicin 150 mg aktiv substans; natriumlaurilsulfat hjälpämne; pyrazinamid 400 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

intas pharmaceuticals limited - kapecitabin - filmdragerad tablett - 150 mg - kapecitabin 150 mg aktiv substans; laktos (vattenfri) hjälpämne - kapecitabin